Literature DB >> 19533372

Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology.

Lars Neumann1, Allegra Ritscher, Gerhard Müller, Doris Hafenbradl.   

Abstract

For the detection of the precise and unambiguous binding of fragments to a specific binding site on the target protein, we have developed a novel reporter displacement binding assay technology. The application of this technology for the fragment screening as well as the fragment evolution process with a specific modelling based design strategy is demonstrated for inhibitors of the protein kinase p38alpha. In a fragment screening approach seed fragments were identified which were then used to build compounds from the deep-pocket towards the hinge binding area of the protein kinase p38alpha based on a modelling approach. BIRB796 was used as a blueprint for the alignment of the fragments. The fragment evolution of these deep-pocket binding fragments towards the fully optimized inhibitor BIRB796 included the modulation of the residence time as well as the affinity. The goal of our study was to evaluate the robustness and efficiency of our novel fragment screening technology at high fragment concentrations, compare the screening data with biochemical activity data and to demonstrate the evolution of the hit fragments with fast kinetics, into slow kinetic inhibitors in an in silico approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19533372     DOI: 10.1007/s10822-009-9288-x

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  18 in total

Review 1.  Biochemical mechanisms of drug action: what does it take for success?

Authors:  David C Swinney
Journal:  Nat Rev Drug Discov       Date:  2004-09       Impact factor: 84.694

Review 2.  Drug-target residence time and its implications for lead optimization.

Authors:  Robert A Copeland; David L Pompliano; Thomas D Meek
Journal:  Nat Rev Drug Discov       Date:  2006-08-04       Impact factor: 84.694

3.  Chemical fragments as foundations for understanding target space and activity prediction.

Authors:  Jeffrey J Sutherland; Richard E Higgs; Ian Watson; Michal Vieth
Journal:  J Med Chem       Date:  2008-04-04       Impact factor: 7.446

4.  Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system.

Authors:  P Dauber-Osguthorpe; V A Roberts; D J Osguthorpe; J Wolff; M Genest; A T Hagler
Journal:  Proteins       Date:  1988

5.  Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition.

Authors:  Ac Backes; B Zech; B Felber; B Klebl; G Müller
Journal:  Expert Opin Drug Discov       Date:  2008-12       Impact factor: 6.098

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

Review 7.  Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety.

Authors:  David C Swinney
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

8.  A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Authors:  Edgar R Wood; Anne T Truesdale; Octerloney B McDonald; Derek Yuan; Anne Hassell; Scott H Dickerson; Byron Ellis; Christopher Pennisi; Earnest Horne; Karen Lackey; Krystal J Alligood; David W Rusnak; Tona M Gilmer; Lisa Shewchuk
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

9.  Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.

Authors:  Guido J R Zaman; Miranda M C van der Lee; Jacobus J Kok; Rob L H Nelissen; Elma E M G Loomans
Journal:  Assay Drug Dev Technol       Date:  2006-08       Impact factor: 1.738

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  4 in total

1.  Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.

Authors:  Benjamin E L Lauffer; Robert Mintzer; Rina Fong; Susmith Mukund; Christine Tam; Inna Zilberleyb; Birgit Flicke; Allegra Ritscher; Grazyna Fedorowicz; Roxanne Vallero; Daniel F Ortwine; Janet Gunzner; Zora Modrusan; Lars Neumann; Christopher M Koth; Patrick J Lupardus; Joshua S Kaminker; Christopher E Heise; Pascal Steiner
Journal:  J Biol Chem       Date:  2013-07-29       Impact factor: 5.157

2.  Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors.

Authors:  Daniel Mucs; Richard A Bryce; Pascal Bonnet
Journal:  J Comput Aided Mol Des       Date:  2011-06-17       Impact factor: 3.686

3.  Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.

Authors:  Kiyoshi Okamoto; Megumi Ikemori-Kawada; Anja Jestel; Konstanze von König; Yasuhiro Funahashi; Tomohiro Matsushima; Akihiko Tsuruoka; Atsushi Inoue; Junji Matsui
Journal:  ACS Med Chem Lett       Date:  2014-11-17       Impact factor: 4.345

4.  Structure-kinetic relationship study of CDK8/CycC specific compounds.

Authors:  Elisabeth V Schneider; Jark Böttcher; Robert Huber; Klaus Maskos; Lars Neumann
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.